Abstract:e18505 Background: 25-35% of adult patients with acute myeloid leukemia (AML) carries NPM1 mutation, characterized by aberrant cytoplasmic dislocation of NPM1 protein, which is generally associated with a favorable outcome in the absence of FLT3-ITD mutation. Indeed, for NPM1-mutated AML patients with different co-mutation profiles, identification of specific co-mutation combinations other than FLT3-ITD mutation is necessary for accurate risk stratification and contributes to identify the optimal population who may benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT) during post-remission therapy. Methods: Eligible patients included newly diagnosed adult patients (≥18 years old) with NPM1 mutated de novo AML (M3 excluded) treated at the First Affiliated Hospital of Zhejiang University School of Medicine for at least one complete course of induction therapy from October 2018 to December 2022. All patients received next generation sequencing (NGS) detection for diagnosis before treatment. Response was evaluated within two courses of induction chemotherapy. Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were collected for endpoint analysis. Results: 178 patients were analyzed. Median age was 59 years old (IQR, 51-68). The co-mutated genes with a detection rate of ≥ 10% included FLT3, DNMT3A, TET2, IDH2, IDH1, PTPN11, NRAS, and WT1. The median follow-up was 26.2 months. Our results showed that in NPM1 mutated AML, co-mutations of IDH1, IDH2, and PTPN11-PTP domain were associated with favorable prognosis, while co-mutations of FLT3-ITD and DNMT3A were associated with poor prognosis. Interestingly, the adverse outcome trends brought by FLT3-ITD and DNMT3A co-mutations could be reversed by IDH mutation and PTPN11 mutations, respectively (Table). Besides, for NPM1 mutated AML patients combined with FLT3-ITD/ DNMT3A mutations, allo-HSCT after remission could significantly improve outcome ( P < 0.05), while similar results were not found in FLT3-ITD/ DNMT3A wild type patients. Conclusions: This study demonstrated that NPM1-mutated AML with different co-mutation profiles led to heterogeneous outcomes. For NPM1-mutated AML patients with adverse prognosis-related co-mutation combinations, allo-HSCT after remission may be a recommended strategy to improve outcome. [Table: see text]

DNMT3A R882 mutation in children with acute myeloid leukemia and its role in prognosis

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Expression Characteristics and Prognosissignificance of Mirna-181A in Acute Myeloid Leukemia with Normal Karyotype

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

Co-mutation Landscape and Its Prognostic Impact on Newly Diagnosed Adult Patients with NPM1 Mutated De Novo Acute Myeloid Leukemia.

High IDH1 Expression is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation

Association Between Dnmt3a Mutations And Prognosis Of Adults With De Novo Acute Myeloid Leukemia: A Systematic Review And Meta-Analysis

The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia

DNMT3A-R882: a mutation with many paradoxes

High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis

Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients

Biological And Clinical Influences Of Npm1 In Acute Myeloid Leukemia Patients With Dnmt3a Mutations

Allogeneic Hematopoietic Stem Cell Transplantation Could Improve Survival of Cytogenetically Normal Adult Acute Myeloid Leukemia Patients with Dnmt3a Mutations

WT1 And DNMT3A Mutations in Prognostic Significance of Acute Myeloid Leukemia: A Meta-Analysis

[Prognostic Value of DTA Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia]

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients

Effect of DNMT3A R882H Hot Spot Mutations on DDX43 Promoter Methylation in Acute Myeloid Leukemia

Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival